Italy· 046130062
HEMLIBRA*1 flaconcino SC 30 mg/ml 0,4 ml
A emicizumab product containing emicizumab, registered in Italy by ROCHE REGISTRATION GMBH, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Emicizumab is registered in 15 of 19 countries.
Countries holding a registration under ATC B02BX06 (emicizumab), each read from that country’s own register.
- This record: Italy
- 10 of them publish a price we can compare per daily dose
Emicizumab · ATC B02BX06
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of emicizumab costs, country by country.
Normalised to the WHO defined daily dose (15 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Emicizumab · price per daily dose (15 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1013.07
The record
At a glance
- Active substance
- Emicizumab
- Manufacturer
- ROCHE REGISTRATION GMBH
- Country
- Italy (IT)
- ATC code
- B02BX06
- ATC class
- Emicizumab
- Defined daily dose
- 15 mg, P
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic046130062HEMLIBRA*1 flaconcino SC 30 mg/ml 0,4 mlEUR 1378.6
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for emicizumab.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Emicizumab · interactions on record
4 records
- 1 severe
- 3 moderate
Most severe, free to view
- Faktor VIII-Inhibitor Bypass Aktivität - FEIBAB02BD03severe
- Coagulation factor VIIIB02BD02moderate
- Coagulation factor VIIaB02BD08moderate
- Octocog alfaB02BD28moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Emicizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumHemlibra 150 mg/mlRoche Registration
- SwitzerlandHemlibra
- CzechiaHEMLIBRARoche Registration GmbH, Grenzach-Wyhlen
- Japanエミシズマブ（遺伝子組換え）中外製薬
- United StatesHemlibraGenentech, Inc.
- FinlandHemlibraOrifarm Oy
- United KingdomHemlibra 105mg/0.7ml solution for injection vialsRoche Products Ltd
- SpainHEMLIBRA 150 MG/ML SOLUCION INYECTABLERoche Registration Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Hemlibra
- Liechtenstein · Hemlibra
- Norway · Hemlibra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a9a71b34-7412-4fc2-84fa-257f80ec333c GET /v1/drugs/a9a71b34-7412-4fc2-84fa-257f80ec333c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 1378.6,
"source": "aifa",
"currency": "EUR",
"strength": "EMICIZUMAB 30MG/ML 0,4ML 1 UNITA' USO PARENTERALE",
"substance": "Emicizumab",
"equivalence_group": "NDX",
"transparency_flag": null
}See everything about emicizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.